Intravenous immunoglobulin for rheumatic diseases

**Record Status**
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

**Citation**

**Authors' objectives**

Intravenous immunoglobulin (IVIG) therapy is used to provide passive immunity or to alter the immune response by increasing an individual’s antibody titer and antigen-antibody reaction potential. IVIG has been investigated as a treatment for patients with rheumatic diseases, with the goals of alleviating symptoms and inducing sustained remissions from disease activity through anti-inflammatory and immunomodulatory effects.

**Timeliness warning**
This report has been archived and may contain outdated information. To request a copy of the report please contact the organisation directly.

**Final publication URL**

**Indexing Status**
Subject indexing assigned by CRD

**MeSH**
Immunoglobulins, Intravenous /therapeutic use; Rheumatic Diseases /drug therapy

**Language Published**
English

**Country of organisation**
United States

**English summary**
An English language summary is available.

**Address for correspondence**
HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com

**AccessionNumber**
32006000994

**Date bibliographic record published**
11/10/2006

**Date abstract record published**
12/05/2010